Cardiovascular diseases are prevalent worldwide and are the most frequent causes of death in the United States. Although spending in drug discovery/development has increased, the amount of drug approvals has seen a progressive decline. Particularly, adverse side effects to the heart and general vasculature have become common causes for preclinical project closures, and preclinical models do not fully recapitulate human in vivo dynamics. Recently, organs-on-a-chip technologies have been proposed to mimic the dynamic conditions of the cardiovascular system—in particular, heart and general vasculature. These systems pay particular attention to mimicking structural organization, shear stress, transmural pressure, mechanical stretching, and electrical stimulation. Heart- and vasculature-on-a-chip platforms have been successfully generated to study a variety of physiological phenomena, model diseases, and probe the effects of drugs. Here, we review and discuss recent breakthroughs in the development of cardiovascular organs-on-a-chip platforms, and their current and future applications in the area of drug discovery and development.
Get full access to this article
View all access options for this article.
References
1.
MozaffarianD, BenjaminEJ, GoAS, et al.Heart Disease and Stroke Statistics—2015 Update: A report from the American Heart Association. Circulation, 2014:131; e29–e322.
2.
LibbyP. Inflammation in atherosclerosis. Nature, 2002:420; 868–874.
NicoliniF, GherliT. Alternatives to transplantation in the surgical therapy for heart failure. Eur J Cardiothorac Surg, 2009:35; 214–228.
5.
The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med, 1987:316; 1429–1435.
6.
The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med, 1991:325; 293–302.
7.
LechatP, PackerM, ChalonS, et al.Clinical effects of adrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation, 1998:98; 1184–1191.
8.
CookD, BrownD, AlexanderR, et al.Lessons learned from the fate of AstraZeneca's drug pipeline: A five-dimensional framework. Nat Rev Drug Discov, 2014:13; 419–431.
9.
CiociolaAA, CohenLB, KulkarniP. How drugs are developed and approved by the FDA: Current process and future directions. Am J Gastroenterol, 2014:109; 620–623.
10.
PaulSM, MytelkaDS, DunwiddieCT, et al.How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov, 2010:9; 203–214.
11.
KolaI, LandisJ. Can the pharmaceutical industry reduce attrition rates?. Nat Rev Drug Discov, 2004:3; 711–715.
12.
MennaP, SalvatorelliE, MinottiG. Cardiotoxicity of antitumor drugs. Chem Res Toxicol, 2008:21; 978–989.
13.
PicciniJP, WhellanDJ, BerridgeBR, et al.Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative. Am Heart J, 2009:158; 317–326.
14.
ShahRR. Can pharmacogenetics help rescue drugs withdrawn from the market?. Pharmacogenomics, 2006:7; 889–908.
15.
ChuX, BleasbyK, EversR. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol, 2013:9; 237–252.
16.
HirtMN, HansenA, EschenhagenT. Cardiac tissue engineering: State of the art. Circ Res, 2014:114; 354–367.
17.
ZhangWJ, LiuW, CuiL, et al.Tissue engineering of blood vessel. J Cell Mol Med, 2007:11; 945–957.
18.
BenamKH, DauthS, HassellB, et al.Engineered in vitro disease models. Annu Rev Pathol, 2015:10; 195–262.
19.
LiS, SenguptaD, ChienS. Vascular tissue engineering: From in vitro to in situ. WIREs Syst Biol Med, 2014:6; 61–76.
20.
MathurA, MaZ, LoskillP, et al.In vitro cardiac tissue models: Current status and future prospects. Adv Drug Deliv Rev, 2016; 96:203–213.
PoliniA, ProdanovL, BhiseNS, et al.Organs-on-a-chip: A new tool for drug discovery. Exp Opin Drug Discov, 2014:9; 335–352.
23.
ZhangYS, AlemanJ, ArneriA, et al.From cardiac tissue engineering to heart-on-a-chip: Beating challenges. Biomed Mater, 2015:10; 034006.
24.
BhiseNS, RibasJ, ManoharanV, et al.Organ-on-a-chip platforms for studying drug delivery systems. J Control Release, 2014:190; 82–93.
25.
GhaemmaghamiAM, HancockMJ, HarringtonH, et al.Biomimetic tissues on a chip for drug discovery. Drug Discov Today, 2012:17; 173–181.
26.
National Center for Health Statistics. Underlying Cause of Death 1999–2013. Center for Disease Control and Prevention; 2015.
27.
World Health Organization. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Geneva: WHO; 2007.
28.
FusterV. Top 10 cardiovascular therapies and interventions for the next decade. Nat Rev Cardiol, 2014:11; 671–683.
29.
ScannellJW, BlanckleyA, BoldonH, et al.Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov, 2012:11; 191–200.
30.
Bloomberg Business. Drug Testing, Now Without the Chimp. Bloomberg Business; 2015.
31.
HolmesA, BonnerF, JonesD. Assessing drug safety in human tissues—what are the barriers?. Nat Rev Drug Discov, 2015; 14:585–587.
32.
DahlinJL, IngleseJ, WaltersMA. Mitigating risk in academic preclinical drug discovery. Nat Rev Drug Discov, 2015:14; 279–294.
33.
PoundP, EbrahimS, SandercockP, et al.Where is the evidence that animal research benefits humans?. BMJ, 2004:328; 514–517.
34.
ChangMG, ZhangY, ChangCY, et al.Spiral waves and reentry dynamics in an in vitro model of the healed infarct border zone. Circ Res, 2009:105; 1062–1071.
35.
KatareRG, AndoM, KakinumaY, et al.Engineered heart tissue: A novel tool to study the ischemic changes of the heart in vitro. PloS One, 2010:5; e9275.
36.
BrackenMB. Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med, 2009:102; 120–122.
37.
BarnardND, KaufmanSR. Animal research is wasteful and misleading. Sci Am, 1997:276; 80–82.
38.
CatoA, SuttonL, CatoAIII. Clinical Drug Trials and Tribulations, Revised and Expanded. New York: Marcel Dekker, Inc.; 2002.
39.
MattisonDR. Improving pediatric drug development: Challenges, opportunities and lessons learned. Front Pharmacol, 2010:1; 1–2.
40.
Institute of Medicine (U.S.) Committee on Accelerating Rare Diseases Research and Orphan Product Development. Rare Diseases and Orphan Products: Accelerating Research and Development (2011). Washington, DC: National Academies Press; 2010.
41.
JunodSW. FDA and Clinical Drug Trials: A Short History. U.S. Food and Drug Administration; 2014.
42.
Ralph LandauBA, ScriabineA. Pharmaceutical Innovation: Revolutionizing Human Health. New York: Chemical Heritage Foundation; 1999.
43.
PaulSM, MytelkaDS, DunwiddieCT, et al.How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov, 2010:9; 203–214.
44.
AlcendorDJ, BlockFEIII, CliffelDE, et al.Neurovascular unit on a chip: Implications for translational applications. Stem Cell Res Ther, 2013:4; 1–5.
45.
MathurA, LoskillP, ShaoK, et al.Human iPSC-based cardiac microphysiological system for drug screening applications. Sci Rep, 2015:5; 8883.
46.
WangG, McCainML, YangL, et al.Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies. Nat Methods, 2014:20; 616–623.
47.
GuntherA, YasotharanS, VagaonA, et al.A microfluidic platform for probing small artery structure and function. Lab Chip, 2010:10; 2341–2349.
48.
McCainML, SheehySP, GrosbergA, et al.Recapitulating maladaptive, multiscale remodeling of failing myocardium on a chip. Proc Natl Acad Sci U S A, 2013:110; 9770–9775.
49.
ReardonS. ‘Organs-on-chips’ go mainstream. Nature, 2015:523; 266.
50.
VladisavljevicGT, KhalidN, NevesMA, et al.Industrial lab-on-a-chip: Design, applications and scale-up for drug discovery and delivery. Adv Drug Deliv Rev, 2013:65; 1626–1663.
51.
GregorioCC, AntinPB. To the heart of myofibril assembly. Trends Cell Biol, 2000:10; 355–362.
52.
HoltE, LundePK, SejerstedOM, et al.Electrical stimulation of adult rat cardiomyocytes in culture improves contractile properties and is associated with altered calcium handling. Basic Res Cardiol, 1997:92; 289–298.
53.
BrutsaertDL. Cardiac endothelial-myocardial signaling: Its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev, 2003:83; 59–115.
54.
RobertsDE, ScherAM. Effect of tissue anisotropy on extracellular potential fields in canine myocardium in situ. Circ Res, 1982:50; 342–351.
NeužiP, GiselbrechtS, LängeK, et al.Revisiting lab-on-a-chip technology for drug discovery. Nat Rev Drug Discov, 2012:11; 620–632.
57.
DuffyDC, McDonaldJC, SchuellerOJ, et al.Rapid prototyping of microfluidic systems in poly(dimethylsiloxane). Anal Chem, 1998:70; 4974–4984.
58.
HalldorssonS, LucumiE, Gómez-SjöbergR, et al.Advantages and challenges of microfluidic cell culture in polydimethylsiloxane devices. Biosens Bioelectron, 2015:63; 218–231.
59.
AnnabiN, SelimovićŠ, Acevedo CoxJP, et al.Hydrogel-coated microfluidic channels for cardiomyocyte culture. Lab Chip, 2013:13; 3569–3577.
WiseSG, MithieuxSM, WeissAS. Engineered tropoelastin and elastin-based biomaterials. Adv Protein Chem Struct Biol, 2009:78; 1–24.
62.
AnnabiN, ShinSR, TamayolA, et al.Highly elastic and conductive human-based protein hybrid hydrogels. Adv Mater, 2016; 28:40–49.
63.
SaffitzJE, KanterHL, GreenKG, et al.Tissue-specific determinants of anisotropic conduction velocity in canine atrial and ventricular myocardium. Circ Res, 1994:74; 1065–1070.
64.
SpachMS, HeidlageJF, DolberPC, et al.Changes in anisotropic conduction caused by remodeling cell size and the cellular distribution of gap junctions and Na(+) channels. J Electrocardiol, 2001:34; 69–76.
65.
BianW, JackmanCP, BursacN. Controlling the structural and functional anisotropy of engineered cardiac tissues. Biofabrication, 2014:6; 024109.
66.
GrosbergA, AlfordPW, McCainML, et al.Ensembles of engineered cardiac tissues for physiological and pharmacological study: Heart on a chip. Lab Chip, 2011:11; 4165.
67.
TandonN, CannizzaroC, ChaoPH, et al.Electrical stimulation systems for cardiac tissue engineering. Nat Protoc, 2009:4; 155–173.
68.
AubinH, NicholJW, HutsonCB, et al.Directed 3D cell alignment and elongation in microengineered hydrogels. Biomaterials, 2010:31; 6941–6951.
69.
AgarwalA, GossJA, ChoA, et al.Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip, 2013:13; 3599–3608.
70.
AuHT, CuiB, ChuZE, et al.Cell culture chips for simultaneous application of topographical and electrical cues enhance phenotype of cardiomyocytes. Lab Chip, 2009:91; 564–575.
71.
XiaoY, ZhangB, LiuH, et al.Microfabricated perfusable cardiac biowire: A platform that mimics native cardiac bundle. Lab Chip, 2014:14; 869–882.
72.
DavisRP, CasiniS, van den BergCW, et al.Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation, 2012:125; 3079–3091.
73.
ItzhakiI, MaizelsL, HuberI, et al.Modelling the long QT syndrome with induced pluripotent stem cells. Nature, 2011:471; 225–229.
74.
SunN, YazawaM, LiuJ, et al.Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med, 2012:4; 130ra47.
75.
MosadeghB, DabiriBE, LockettMR, et al.Three-dimensional paper-based model for cardiac ischemia. Adv Healthc Mater, 2014:3; 1036–1043.
76.
SongH, ZandstraPW, RadisicM. Engineered heart tissue model of diabetic myocardium. Tissue Eng Part A, 2011:17; 1869–1878.
77.
StöhrA, FriedrichFW, FlennerF, et al.Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol, 2013:63; 189–198.
78.
LiAH, LiuPP, VillarrealFJ, et al.Dynamic changes in myocardial matrix and relevance to disease: Translational perspectives. Circ Res, 2014:114; 916–927.
79.
IedaM, TsuchihashiT, IveyKN, et al.Cardiac fibroblasts regulate myocardial proliferation through beta1 integrin signaling. Dev Cell, 2009:16; 233–244.
80.
SchroerAK, MerrymanWD. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. J Cell Sci, 2015:128; 1865–1875.
81.
McCainML, ParkerKK. Mechanotransduction: The role of mechanical stress, myocyte shape, and cytoskeletal architecture on cardiac function. Pflugers Arch, 2011:462; 89–104.
82.
HoCY. Hypertrophic cardiomyopathy: Preclinical and early phenotype. J Cardiovasc Transl Res, 2009:2; 462–470.
83.
RenL, LiuW, WangY, et al.Investigation of hypoxia-induced myocardial injury dynamics in a tissue interface mimicking microfluidic device. Anal Chem, 2013:85; 235–244.
84.
GarbernJC, LeeRT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell, 2013:12; 689–698.
85.
HeJ, MaC, LiuW, et al.On-chip monitoring of skeletal myoblast transplantation for the treatment of hypoxia-induced myocardial injury. Analyst, 2014:1391; 4482–4490.
86.
ChenMB, SrigunapalanS, WheelerAR, et al.A 3D microfluidic platform incorporating methacrylated gelatin hydrogels to study physiological cardiovascular cell-cell interactions. Lab Chip, 2013:13; 2591–2598.
87.
TaylorPM, BattenP, BrandNJ, et al.The cardiac valve interstitial cell. Int J Biochem Cell Biol, 2003:35; 113–118.
88.
WipffPJ, RifkinDB, MeisterJJ, et al.Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J Cell Biol, 2007:179; 1311–1323.
89.
MerrymanWD, SchoenFJ. Mechanisms of calcification in aortic valve disease: Role of mechanokinetics and mechanodynamics. Curr Cardiol Rep, 2013:15; 355.
90.
RajamannanNM, EvansFJ, AikawaE, et al.Calcific aortic valve disease: Not simply a degenerative process: A review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: Calcific aortic valve disease-2011 update. Circulation, 2011:124; 1783–1791.
91.
SimmonsCA, GrantGR, ManduchiE, et al.Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res, 2005:96; 792–799.
92.
MartinsAM, Vunjak-NovakovicG, ReisRL. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine. Stem Cell Rev, 2014:10; 177–190.
93.
MercolaM, ColasA, WillemsE. Induced pluripotent stem cells in cardiovascular drug discovery. Circ Res, 2013:112; 534–548.
94.
WangG, McCainML, YangL, et al.Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med, 2014:20; 616–623.
95.
BianchiE, MolteniR, PardiR, et al.Microfluidics for in vitro biomimetic shear stress-dependent leukocyte adhesion assays. J Biomech, 2013:46; 276–283.
96.
SwartzMA, FleuryME. Interstitial flow and its effects in soft tissues. Annu Rev Biomed Eng, 2007:9; 229–256.
97.
WongKH, ChanJM, KammRD, et al.Microfluidic models of vascular functions. Annu Rev Biomed Eng, 2012:14; 205–230.
98.
ZhangW, ZhangYS, BakhtM, et al.Elastomeric free-form blood vessels for interconnecting organs on chip systems. Lab Chip, 2016. DOI: 10.1039/C6LC00001K
99.
KimS, LeeH, ChungM, et al.Engineering of functional, perfusable 3D microvascular networks on a chip. Lab Chip, 2013:13; 1489–1500.
100.
BertassoniLE, CardosoJC, ManoharanV, et al.Direct-write bioprinting of cell-laden methacrylated gelatin hydrogels. Biofabrication, 2014:6; 024105.
101.
HasenbergT, MuhlederS, DotzlerA, et al.Emulating human microcapillaries in a multi-organ-chip platform. J Biotechnol, 2015:216; 1–10.
102.
MorganJP, DelneroPF, ZhengY, et al.Formation of microvascular networks in vitro. Nat Protoc, 2013:8; 1820–1836.
103.
WangXY, JinZH, GanBW, et al.Engineering interconnected 3D vascular networks in hydrogels using molded sodium alginate lattice as the sacrificial template. Lab Chip, 2014:14; 2709–2716.
104.
YeonJH, RyuHR, ChungM, et al.In vitro formation and characterization of a perfusable three-dimensional tubular capillary network in microfluidic devices. Lab Chip, 2012:12; 2815–2822.
105.
SchimekK, BusekM, BrinckerS, et al.Integrating biological vasculature into a multi-organ-chip microsystem. Lab Chip, 2013:13; 3588–3598.
106.
BogoradMI, DeStefanoJ, KarlssonJ, et al.Review: in vitro microvessel models. Lab Chip, 2015:15; 4242–4255.
107.
YasotharanS, PintoS, SledJG, et al.Artery-on-a-chip platform for automated, multimodal assessment of cerebral blood vessel structure and function. Lab Chip, 2015:15; 2660–2669.
108.
RosanoJM, TousiN, ScottRC, et al.A physiologically realistic in vitro model of microvascular networks. Biomed Microdevices, 2009:11; 1051–1057.
109.
BischelLL, YoungEW, MaderBR, et al.Tubeless microfluidic angiogenesis assay with three-dimensional endothelial-lined microvessels. Biomaterials, 2013:34; 1471–1477.
110.
GaliePA, NguyenDH, ChoiCK, et al.Fluid shear stress threshold regulates angiogenic sprouting. Proc Natl Acad Sci U S A, 2014:111; 7968–7973.
111.
BuchananCF, VerbridgeSS, VlachosPP, et al.Flow shear stress regulates endothelial barrier function and expression of angiogenic factors in a 3D microfluidic tumor vascular model. Cell Adh Migr, 2014:8; 517–524.
112.
JeonJS, BersiniS, GilardiM, et al.Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation. Proc Natl Acad Sci U S A, 2015:112; 214–219.
113.
WangXY, PeiY, XieM, et al.An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells. Lab Chip, 2015:15; 1178–1187.
114.
TsuiJH, LeeW, PunSH, et al.Microfluidics-assisted in vitro drug screening and carrier production. Adv Drug Deliv Rev, 2013:65; 1575–1588.
115.
LiM, HotalingNA, KuDN, et al.Microfluidic thrombosis under multiple shear rates and antiplatelet therapy doses. PLoS One, 2014:9; e82493.
116.
MuthardRW, DiamondSL. Side view thrombosis microfluidic device with controllable wall shear rate and transthrombus pressure gradient. Lab Chip, 2013:13; 1883–1891.
117.
TsaiM, KitaA, LeachJ, et al.In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest, 2012:122; 408–418.
118.
KorinN, KanapathipillaiM, MatthewsBD, et al.Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science, 2012:337; 738–742.
119.
DoshiN, PrabhakarpandianB, Rea-RamseyA, et al.Flow and adhesion of drug carriers in blood vessels depend on their shape: A study using model synthetic microvascular networks. J Control Release, 2010:146; 196–200.
120.
HuR, LiF, LvJ, et al.Microfluidic analysis of pressure drop and flow behavior in hypertensive micro vessels. Biomed Microdevices, 2015:17; 9959.
121.
FrancoD, MildeF, KlingaufM, et al.Accelerated endothelial wound healing on microstructured substrates under flow. Biomaterials, 2013:34; 1488–1497.
122.
ArendsF, SellnerS, SeifertP, et al.A microfluidics approach to study the accumulation of molecules at basal lamina interfaces. Lab Chip, 2015:15; 3326–3334.
123.
ChrobakKM, PotterDR, TienJ. Formation of perfused, functional microvascular tubes in vitro. Microvasc Res, 2006:71; 185–196.
124.
LeeH, KimS, ChungM, et al.A bioengineered array of 3D microvessels for vascular permeability assay. Microvasc Res, 2014:91; 90–98.
125.
PriceGM, WongKH, TruslowJG, et al.Effect of mechanical factors on the function of engineered human blood microvessels in microfluidic collagen gels. Biomaterials, 2010:31; 6182–6189.
126.
SatoM, SasakiN, AtoM, et al.Microcirculation-on-a-chip: A microfluidic platform for assaying blood- and lymphatic-vessel permeability. PLoS One, 2015:10; e0137301.
127.
YoungEW, WatsonMW, SrigunapalanS, et al.Technique for real-time measurements of endothelial permeability in a microfluidic membrane chip using laser-induced fluorescence detection. Anal Chem, 2010:82; 808–816.
128.
LiLM, WangXY, HuLS, et al.Vascular lumen simulation and highly-sensitive nitric oxide detection using three-dimensional gelatin chip coupled to TiC/C nanowire arrays microelectrode. Lab Chip, 2012:12; 4249–4256.
129.
ShaoJ, WuL, WuJ, et al.Integrated microfluidic chip for endothelial cells culture and analysis exposed to a pulsatile and oscillatory shear stress. Lab Chip, 2009:9; 3118–125.
130.
ZhengW, JiangB, WangD, et al.A microfluidic flow-stretch chip for investigating blood vessel biomechanics. Lab Chip, 2012:12; 3441–3450.
